Why this matters? Nurix Therapeutics has discovered a new type of mutation in a protein called BTK, which is involved in certain blood cancers. These mutations can make cancer cells resistant to current treatments. However, Nurix has developed a new drug, NX-2127, that can target and destroy these mutated proteins, offering a new way to treat patients who have developed resistance to existing therapies.
NX-2127 has shown promising results in early clinical trials, effectively targeting the BTK protein in patients with chronic lymphocytic leukemia, a type of blood cancer. This suggests that the drug could be a valuable new option for treating various B-cell malignancies, which are cancers that affect a type of white blood cell.
#biotech #innovation #bloodcancer
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
https://lnkd.in/dyvWBkTr
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader | Nurix Therapeutics, Inc.
ir.nurixtx.com
CEO, Chair, and Co-Founder at ElevateBio
1moI am very pleased that our Scholar Rock team continues to advance the industry's most innovative myostatin platform across a range of devastating genetic disorders and obesity with multiple therapeutic candidates.